Ergoteles’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Ergoteles’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-41,773	Closed	-$422K	–	2003
2022 Q4	$422K	Hold	41,773	–	–	0.02%	769
2022 Q3	$415K	Hold	41,773	–	–	0.01%	830
2022 Q2	$414K	Buy	+41,773	New	+$410K	0.01%	925

Ergoteles's BIOT Position: Q1 2023 in Review

Ergoteles sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 41,773 shares — an estimated $422K sold.

Ergoteles first reported a position in BIOT in Q2 2022 and held it in 3 quarters. The position peaked at $422K in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Ergoteles reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 41,773 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $422K.
Ergoteles first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q2 2022 and held it in 3 quarters.
Ergoteles's Biotech Acquisition Company Class A Ordinary Shares position peaked at $422K in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.